Financials in USD. Standardized financial statements.
A compact view of how Xenon Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $7.50M | $0 | $0 | $9.43M | $18.44M | $32.17M | $6.83M | $0 | $311,000 | $1.80M |
| Revenue Growth? | 0.0% | 0.0% | -100.0% | -48.8% | -42.7% | +371.0% | 0.0% | -100.0% | -82.8% | 0.0% |
| Cost of Revenue? | $2.54M | $2.56M | $167.51M | $0 | $0 | $0 | $0 | $6.00M | $25.57M | $1.11M |
| Gross Profit? | $4.96M | -$2.56M | -$167.51M | $9.43M | $18.44M | $32.17M | $6.83M | -$6.00M | -$25.26M | $689,000 |
| Gross Margin? | +66.1% | 0.0% | 0.0% | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% | -8122.8% | +38.2% |
| Operating Expenses? | $378.03M | $276.74M | $46.54M | $138.58M | $97.43M | $63.47M | $49.65M | $32.02M | $32.89M | $26.62M |
| Operating Income? | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -$78.99M | -$31.30M | -$42.82M | -$38.02M | -$32.58M | -$24.82M |
| EBITDA? | -$342.35M | -$235.86M | -$210.51M | -$127.74M | -$78.09M | -$27.97M | -$39.76M | -$32.54M | -$30.05M | -$23.95M |
| Income Before Tax | -$344.89M | -$238.42M | -$182.69M | -$125.25M | -$78.89M | -$29.09M | -$41.62M | -$34.50M | -$30.70M | -$23.00M |
| Income Tax Expense | $1.02M | -$4.09M | -$292,000 | $118,000 | -$6,000 | -$257,000 | -$23,000 | $4.91M | $0 | $0 |
| Net Income? | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -$78.88M | -$28.84M | -$41.59M | -$34.50M | -$30.70M | -$23.00M |
| EPS? | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.83 | $-1.54 | $-1.78 | $-1.71 | $-1.48 |
| Diluted EPS? | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.83 | $-1.54 | $-1.78 | $-1.71 | $-1.48 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality